An immunotherapy drug called 'avelumab' has been shown to significantly improve survival in patients with the most common type of bladder cancer, according to results from a phase III clinical trial led by Queen Mary University ...
Sep 18, 2020
0
34
In a Phase II trial led by researchers at The University of Texas MD Anderson Cancer Center, the combination of dabrafenib, a BRAF inhibitor, and trametinib, a MEK inhibitor, achieved a 51% overall response rate (ORR) in ...
Aug 18, 2020
0
1
The international First-line Radiosurgery for Small-Cell Lung Cancer (FIRE-SCLC) analysis led by University of Colorado Cancer Center researchers and published today in JAMA Oncology details clinical outcomes for 710 patients ...
Jun 5, 2020
0
7
(HealthDay)—For men with advanced prostate cancer, the oral gonadotropin-releasing hormone (GnRH) antagonist relugolix maintains testosterone suppression compared with the GnRH agonist leuprolide, while enzalutamide is ...
May 29, 2020
0
5
An immunotherapy drug called 'avelumab' has been shown to significantly improve survival in patients with the most common type of bladder cancer, according to results from a phase III clinical trial led by Professor Tom Powles ...
May 29, 2020
0
3
Two novel biomarkers have been found to correlate with improved outcomes with immunotherapy in metastatic breast cancer and may help to identify the patients most likely to benefit from this treatment, according to exploratory ...
May 22, 2020
0
3
Patients with metastatic pancreatic cancer who had germline or somatic mutations in DNA repair genes had better clinical outcomes after platinum-based chemotherapy, as compared with patients without these mutations, according ...
May 22, 2020
0
1
Smoking status is an important patient-related prognostic factor for outcome in patients with acute myeloid leukemia (AML) treated with intensive chemotherapy, according to a study published online April 21 in the British ...
Apr 30, 2020
0
3
By the time a pancreatic tumor begins to cause symptoms, it is usually pretty advanced, since many of the tumors are 'silent."
Mar 2, 2020
0
85
For patients with multiple myeloma receiving focal radiation therapy (RT) for symptomatic plasmacytoma, reirradiation is rarely required, according to a letter to the editor published online Jan. 9 in Haematologica.
Feb 3, 2020
0
7
